NCT00833963

A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).

Conditions

• Breast Cancer
• Pregnancy

Interventions

Type	Name	Description
DRUG	Trastuzumab	Participants will receive trastuzumab as determined by their treating physicians' standards of care.
DRUG	Pertuzumab	Participants will receive pertuzumab as determined by their treating physicians' standards of care.
DRUG	Ado-Trastuzumab Emtansine	Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.

Timeline

• Start date: 2009-01-14
• Primary completion: 2017-04-13
• Completion: 2017-04-13
• First posted: 2009-02-02
• Last updated: 2019-05-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study